These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 1967651)
41. Behavioral, biochemical and neurotoxicological actions of the alpha-ethyl homologue of p-chloroamphetamine. Johnson MP; Huang XM; Oberlender R; Nash JF; Nichols DE Eur J Pharmacol; 1990 Nov; 191(1):1-10. PubMed ID: 1982656 [TBL] [Abstract][Full Text] [Related]
42. Investigation of MDMA-related agents in rats trained to discriminate MDMA from saline. Glennon RA; Higgs R Pharmacol Biochem Behav; 1992 Nov; 43(3):759-63. PubMed ID: 1360162 [TBL] [Abstract][Full Text] [Related]
43. A study of the mechanism of MDMA ('ecstasy')-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds. Colado MI; Green AR Br J Pharmacol; 1994 Jan; 111(1):131-6. PubMed ID: 7516800 [TBL] [Abstract][Full Text] [Related]
44. The effects of MDMA and other methylenedioxy-substituted phenylalkylamines on the structure of rat locomotor activity. Paulus MP; Geyer MA Neuropsychopharmacology; 1992 Aug; 7(1):15-31. PubMed ID: 1355968 [TBL] [Abstract][Full Text] [Related]
45. Synthesis of fluoro analogues of 3,4-(methylenedioxy)amphetamine (MDA) and its derivatives. Trachsel D; Hadorn M; Baumberger F Chem Biodivers; 2006 Mar; 3(3):326-36. PubMed ID: 17193269 [TBL] [Abstract][Full Text] [Related]
46. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Colado MI; Williams JL; Green AR Br J Pharmacol; 1995 Aug; 115(7):1281-9. PubMed ID: 7582557 [TBL] [Abstract][Full Text] [Related]
47. Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Johnson MP; Hoffman AJ; Nichols DE Eur J Pharmacol; 1986 Dec; 132(2-3):269-76. PubMed ID: 2880735 [TBL] [Abstract][Full Text] [Related]
48. Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine. Blair JB; Marona-Lewicka D; Kanthasamy A; Lucaites VL; Nelson DL; Nichols DE J Med Chem; 1999 Mar; 42(6):1106-11. PubMed ID: 10090793 [TBL] [Abstract][Full Text] [Related]
49. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love"). McNamara R; Kerans A; O'Neill B; Harkin A Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283 [TBL] [Abstract][Full Text] [Related]
50. Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ("Ecstasy"). Sharkey J; McBean DE; Kelly PA Psychopharmacology (Berl); 1991; 105(1):113-8. PubMed ID: 1684057 [TBL] [Abstract][Full Text] [Related]
51. N-Methyl-1-(4-methoxyphenyl)-2-aminopropane (PMMA) and N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) produce non-identical discriminative stimuli in rats. Glennon RA; Young R; Dukat M; Chang-Fong J; El-Zahabi M Pharmacol Biochem Behav; 2007 Mar; 86(3):477-84. PubMed ID: 17307247 [TBL] [Abstract][Full Text] [Related]
52. Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. Nichols DE; Hoffman AJ; Oberlender RA; Jacob P; Shulgin AT J Med Chem; 1986 Oct; 29(10):2009-15. PubMed ID: 3761319 [TBL] [Abstract][Full Text] [Related]
53. Serotonergic modulation of rat pup ultrasonic vocal development: studies with 3,4-methylenedioxymethamphetamine. Winslow JT; Insel TR J Pharmacol Exp Ther; 1990 Jul; 254(1):212-20. PubMed ID: 1973197 [TBL] [Abstract][Full Text] [Related]
54. Reinforcement schedule effects in rats trained to discriminate 3,4-methylenedioxymethamphetamine (MDMA) or cocaine. Kueh D; Baker LE Psychopharmacology (Berl); 2007 Jan; 189(4):447-57. PubMed ID: 17019568 [TBL] [Abstract][Full Text] [Related]
55. Receptor pharmacology of MDMA and related hallucinogens. Teitler M; Leonhardt S; Appel NM; De Souza EB; Glennon RA Ann N Y Acad Sci; 1990; 600():626-38; discussion 638-9. PubMed ID: 1979215 [TBL] [Abstract][Full Text] [Related]
56. Generalization of serotonin and dopamine ligands to the discriminative stimulus effects of different doses of ±3,4-methylenedioxymethamphetamine. Webster JI; Harper DN; Schenk S Behav Pharmacol; 2017 Jun; 28(4):245-254. PubMed ID: 27922542 [TBL] [Abstract][Full Text] [Related]
57. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. Marek GJ; Aghajanian GK J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525 [TBL] [Abstract][Full Text] [Related]
58. Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems. Battaglia G; De Souza EB NIDA Res Monogr; 1989; 94():240-58. PubMed ID: 2514364 [TBL] [Abstract][Full Text] [Related]
59. Psychostimulant-like effects of p-fluoroamphetamine in the rat. Marona-Lewicka D; Rhee GS; Sprague JE; Nichols DE Eur J Pharmacol; 1995 Dec; 287(2):105-13. PubMed ID: 8749023 [TBL] [Abstract][Full Text] [Related]